Appendix 3Y Change of Director's Interest Notice
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Cryosite Limited
ABN 86 090 919 476
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director
Andrew Kroger
Date of last notice
1st September 2016
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
Direct or indirect interest
Direct & Indirect
Nature of indirect interest (including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest.
Andrew John Kroger registered holder of 41,090
Austen Bay Pty Limited ATF The Andrew Kroger Family Superannuation Fund ABN 32 013 216 128 registered holder of
11,574,276 (of which Andrew John Kroger is a shareholder) and
Process Wastewater Technologies Pty Limited ABN 63 066 810 026 registered holder of 2,832,667 (of which Andrew John Kroger is a Director and the Controller) and
S.H.R. Pty Limited ABN 13 006 609 418 registered holder of 168,873 (of which Andrew John Kroger is a Director and the Controller)
Date of change
30th June 2017
No. of securities held prior to change
14,616,906
Class
Ordinary Shares
.
Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
Number acquired
900,000 plus 427,500
(acquired by SHR Pty Limited ABN 13 006 609 418)
72,500
(acquired by Austen Bay Pty Limited ATF The Andrew Kroger Family Superannuation Fund ABN 32 013 216 128)
Number disposed
Value/Consideration
Note: If consideration is non‐cash, provide details and estimated valuation
900,000 units = $171,000 ($0.19 cps)
427,500 units = $81,225 ($0.19 cps)
72,500 units = $11,600 ($0.16 cps)
No. of securities held after change
16,016,906
Nature of change
Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back
900,000 Off‐market trade
427,500 Off‐market trade
72,500 On‐market trade
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non‐cash, provide details and an estimated valuation
Appendix 3Y Page 2
Interest after change
Appendix 3Y Change of Director's Interest Notice
Part 3 - +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written clearance was required?
No
If so, was prior written clearance provided to allow the trade to proceed during this period?
Not applicable
If prior written clearance was provided, on what date was this provided?
Not applicable
.
Appendix 3Y Page 3
Cryosite Limited published this content on 03 July 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 July 2017 04:57:06 UTC.
Cryosite Limited is engaged in providing outsourced clinical trials depot services. The Company manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution and reverse logistics management. Its segments include Clinical trials and biological services logistics and Cord Blood and tissue storage. The Clinical trials and biological services logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, biological services and cell gene therapies depot services. Cord Blood and tissue storage segment provides storage of cord blood and tissue samples. Its facilities are purpose-built to store a range of biological materials, including Cell Banks (MCB, WCB), Mesenchymal Stromal Cell (MSC) Therapies, Tumour-Infiltrating Lymphocyte Therapies and others.